These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 22160008

  • 1. Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy.
    Parker CJ.
    Hematology Am Soc Hematol Educ Program; 2011; 2011():21-9. PubMed ID: 22160008
    [Abstract] [Full Text] [Related]

  • 2. Paroxysmal nocturnal hemoglobinuria.
    Parker CJ.
    Curr Opin Hematol; 2012 May; 19(3):141-8. PubMed ID: 22395662
    [Abstract] [Full Text] [Related]

  • 3. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M, Martin Merinero H, López A, Anter J, García SP, Ataúlfo Gonzalez-Fernández F, Forés R, Lopez-Trascasa M, Villegas A, Ojeda E, Rodríguez de Córdoba S.
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [Abstract] [Full Text] [Related]

  • 4. Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.
    Cooper JP, Farah RJ, Stevenson PA, Gooley TA, Storb R, Scott BL.
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1331-1339. PubMed ID: 30711779
    [Abstract] [Full Text] [Related]

  • 5. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM.
    Adv Exp Med Biol; 2013 Jul; 735():155-72. PubMed ID: 23402025
    [Abstract] [Full Text] [Related]

  • 6. [Paroxysmal nocturnal hemoglobinuria and thrombosis in the era of eculizumab].
    Nishimura JI.
    Rinsho Ketsueki; 2018 Jul; 59(8):1042-1047. PubMed ID: 30185704
    [Abstract] [Full Text] [Related]

  • 7. [Paroxysmal nocturnal hemoglobinuria (PNH). Pathogenesis, diagnosis and treatment].
    Röth A, Dührsen U, Schrezenmeier H, Schubert J.
    Dtsch Med Wochenschr; 2009 Feb; 134(9):404-9. PubMed ID: 19224425
    [Abstract] [Full Text] [Related]

  • 8. Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition.
    Varela JC, Brodsky RA.
    Expert Rev Clin Immunol; 2013 Nov; 9(11):1113-24. PubMed ID: 24168416
    [Abstract] [Full Text] [Related]

  • 9. Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones.
    Mei M, Gupta R, O'Donnell M, Al Malki MM, Aldoss I, Ali H, Farol L, Snyder D, Forman SJ, Nakamura R, Khaled S.
    Biol Blood Marrow Transplant; 2019 May; 25(5):e183-e185. PubMed ID: 30708188
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
    Risitano AM, Perna F, Selleri C.
    Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Bone marrow failure syndromes: paroxysmal nocturnal hemoglobinuria.
    Parker CJ.
    Hematol Oncol Clin North Am; 2009 Apr; 23(2):333-46. PubMed ID: 19327587
    [Abstract] [Full Text] [Related]

  • 14. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
    Notaro R, Sica M.
    Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
    [Abstract] [Full Text] [Related]

  • 15. Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion.
    Szer J, Hill A, Weitz IC.
    Clin Adv Hematol Oncol; 2012 Nov; 10(11 Suppl 21):1-16. PubMed ID: 23271156
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders.
    Risitano AM.
    Immunobiology; 2012 Nov; 217(11):1080-7. PubMed ID: 22964233
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
    Sica M, Rondelli T, Ricci P, De Angioletti M, Risitano AM, Notaro R.
    J Hematol Oncol; 2017 Jun 19; 10(1):126. PubMed ID: 28629435
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.